New Pharmaceuticals research report from Espicom Business Intelligence is now available from Fast Market Research

Williamstown, MA -- (SBWire) -- 01/19/2012 --Pain Therapy Drugs Market

As the market evolves over the next decade current market leaders will lose patent expiry and become subject to generic competition. What's in the pipeline and which companies and products will prosper?

Pain affects around 1.5 billion people worldwide. In most cases, pain is temporary and easily treated with commonly available analgesics. For some people, however, pain is a debilitating, chronic condition. In Europe, an estimated 20% of the population suffers from chronic pain. As the population ages, the number of people with chronic pain is increasing, particularly from conditions such as osteoarthritis. Chronic pain is also associated with cancer. An estimated 30% of all cancer patients are in pain with the proportion more than doubling among people with late-stage cancer. In recent years, drug development in pain therapy has been focused mainly on reformulations of existing therapies and alternative modes of drug delivery in order to improve the safety and efficacy of existing drug groups.

View Full Report Details and Table of Contents

Drugs of the future
This report identifies 75 agents in clinical development for pain indications, of which 26 are in development for neuropathic pain. Among these, six are specifically targeting postherpetic neuralgia. Other indications specified, include: diabetic peripheral neuropathy, central neuropathic pain due to spinal cord injury or multiple sclerosis (MS), neuropathic pain in cancer, lumbosacral radiculopathy, and painful neuropathies affecting AIDS patients. Nociceptive pain indications being targeted by developers,
include: osteoarthritis pain and chronic low back pain.

This report answers key questions on:

- What is the current clinical understanding of pain?
- What is the status of, and commercial prospects for, currently available pain therapies?
- What drugs are in the pipeline and what is their status?
- Which companies are set to win, and which to lose, as the pain sector develops over the next 5 years?

While highly competitive, pain remains a sector of high unmet clinical need with excellent opportunities in niche markets

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper
- The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges
- CNS Generic Drugs: Prospects and Opportunities to 2012
- Neuropathic Pain - Drug Pipeline Analysis and Market Forecasts to 2015
- Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
- The Pain Market Outlook to 2011
- New Drug Futures 2009
- Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment
- R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need
- CNS Drug Discoveries: what the future holds 2008 FULL REPORT